These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Hematopoietic growth factors: personalization of risks and benefits. Puhalla S; Bhattacharya S; Davidson NE Mol Oncol; 2012 Apr; 6(2):237-41. PubMed ID: 22497867 [TBL] [Abstract][Full Text] [Related]
4. Current and future use of hematopoietic growth factors in cancer medicine. Mughal TI Hematol Oncol; 2004 Sep; 22(3):121-34. PubMed ID: 15991222 [TBL] [Abstract][Full Text] [Related]
5. [Hematopoietic growth factors in cancer management]. Koistinen P; Soppi E Duodecim; 1993; 109(10):851-60. PubMed ID: 8062652 [No Abstract] [Full Text] [Related]
6. Therapeutic potential of the hematopoietic growth factors. Usha D; Thatte UM; Dahanukar SA J Postgrad Med; 1994; 40(4):210-5. PubMed ID: 9136242 [No Abstract] [Full Text] [Related]
7. Hematopoietic growth factors as adjuncts to antiretroviral therapy. Miles SA AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1073-80. PubMed ID: 1380256 [TBL] [Abstract][Full Text] [Related]
8. The present and future of hematopoietic cytokines in clinical practice. George MJ Stem Cells; 1994; 12 Suppl 1():249-55. PubMed ID: 7696964 [TBL] [Abstract][Full Text] [Related]
9. Successful management of gelatinous transformation of the bone marrow in anorexia nervosa with hematopoietic growth factors. Charania RS; Kern WF; Charkrabarty S; Holter J Int J Eat Disord; 2011 Jul; 44(5):469-72. PubMed ID: 20593416 [TBL] [Abstract][Full Text] [Related]
10. Hematopoietic growth factors for the treatment of inherited cytopenias. Zeidler C; Welte K Semin Hematol; 2007 Jul; 44(3):133-7. PubMed ID: 17631177 [TBL] [Abstract][Full Text] [Related]
11. [Importance of recombinant proteins in the adjuvant treatment of cancer]. Cheron JM Ann Pharm Fr; 1998; 56(6):241-3. PubMed ID: 9872009 [TBL] [Abstract][Full Text] [Related]
12. [Clinical use of hematopoietic growth factors]. Gianni AM; Bregni M; Siena S; Tarella C; DiNicola M; Bonadonna G Haematologica; 1991 Jun; 76 Suppl 3():3-10. PubMed ID: 1752526 [No Abstract] [Full Text] [Related]
13. The use of hematological growth factors to enable dose intensification in chemotherapy for soft tissue sarcomas. Liem GS; Verweij J Stem Cells; 1994 Jul; 12(4):402-8. PubMed ID: 7951007 [TBL] [Abstract][Full Text] [Related]
14. Hematopoietic growth factors in oncology. Mertelsmann R; Lindemann A; Oster W; Gamm H; Kolbe K; Herrmann F Cancer Detect Prev; 1990; 14(6):613-6. PubMed ID: 2257558 [TBL] [Abstract][Full Text] [Related]
15. The role of hematopoietic growth factors in transfusion medicine. Whitsett CF Hematol Oncol Clin North Am; 1995 Feb; 9(1):23-68. PubMed ID: 7737944 [TBL] [Abstract][Full Text] [Related]
16. [Current status of clinical indications for hematopoietic growth factors after chemo-/radiotherapy in gynecology]. Karthaus M; Ganser A Zentralbl Gynakol; 1997; 119(12):585-96. PubMed ID: 9483809 [TBL] [Abstract][Full Text] [Related]
17. [Clinical use of hematopoietic growth factors in treatment of bone marrow failure]. Robak T; Krykowski E Pol Arch Med Wewn; 1994 Jul; 92(1):1-8. PubMed ID: 7971472 [No Abstract] [Full Text] [Related]
18. Myelosuppression and "conventional" chemotherapy: what price, what benefit? Canellos GP; Demetri GD J Clin Oncol; 1993 Jan; 11(1):1-2. PubMed ID: 8418220 [No Abstract] [Full Text] [Related]
19. The use of hematopoietic growth factors to support cytotoxic chemotherapy for patients with breast cancer. Demetri GD Hematol Oncol Clin North Am; 1994 Feb; 8(1):233-49. PubMed ID: 8150782 [TBL] [Abstract][Full Text] [Related]
20. [What is reliable in the therapy of hematologic diseases? II. Anemias, myeloproliferative diseases, panmyelopathy and agranulocytosis]. Sodomann CP; Malchow H; Schmidt M; Havemann K Internist (Berl); 1970 Dec; 11(12):449-53. PubMed ID: 4924816 [No Abstract] [Full Text] [Related] [Next] [New Search]